Newsletter

Int. Rev. Allergol. Clin. Immunol. Family Med., 2016, XXII/2: 061-071 Maximize

Int. Rev. Allergol. Clin. Immunol. Family Med., 2016, XXII/2: 061-071

Title: Cytokines as the inflammatory mediators in heart failure 

Authors: Ptaszyńska-Kopczyńska K, Kamiński KA, Musiał WJ.

More details

01-02-2016

40,00 zł

SUMMARY IN POLISH & ENGLISH. FULL ARTICLE ONLY IN POLISH.

Cytokines as the inflammatory mediators in heart failure


Ptaszyńska-Kopczyńska K1, Kamiński KA1,2, Musiał WJ1.

Medical University of Białystok, Poland: 1Department of Cardiology; 2Department of Population Medicine and Prevention of Civilization Diseases

Int Rev Allergol Clin Immunol Family Med, 2016; Vol. 22, No. 2, 61

The improvement of medical care and increased life expectancy results in a growing number of chronic cardiovascular diseases including chronic heart failure (CHF). In addition to the pharmacotherapy, invasive methods such as cardiac resynchronization therapy (CRT) are commonly used to slow down progression and reverse the course of the disease. Unfortunately, some patients do not benefit from the therapy, suggesting that significant factors contributing to the progression of the disease are still active despite the treatment. Chronic inflammatory activation, which is recently considered an important factor in the CHF, exerts direct and indirect effects on the myocardium and contributes to the systemic damage in patients with CHF. Previous studies investigating sources of inflammatory mediators such as interleukin 6 (IL-6) or tumor necrosis factor α (TNFα) suggest myocardium as one of the main releasing tissues. These cytokines are acting not only directly on cardiomyocytes, but also recruit inflammatory cells, which stimulate negative phenomena such as interstitial fibrosis, hypertrophy and apoptosis of cardiomyocytes. Unfortunately, it is hard to define the contribution of particular cytokines in the disease development and progression since they are interconnected in the ‘cytokine network’. Moreover, previous therapeutic attempts to limit inflammation in CHF patients did not bring substantial benefits. The following article reviews the current evidence concerning cytokines as regulators of inflammation and their influence on the CHF development.

Key words: heart failure, inflammatory activation, cytokines, interleukins